echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Overcome resistance!

    Overcome resistance!

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On December 15th, Nuvation announced that the US FDA has granted the company's CDK2/4/6 inhibitor NUV-422 fast track designation for the treatment of high-grade gliomas, including glioblastoma multiforme


    CDK4/6 inhibitors have been shown to be effective against malignant tumors, but some cancer cells can evade cdk4/6 treatment by increasing the CDK2 signaling pathway


    Pre-clinical studies have shown that NUV-422 has good blood-brain barrier penetration


    Preclinical data shows that in the in vivo xenograft model of glioblastoma multiforme, NUV-422 has a better tumor suppressor effect than standard care therapy temozolomide


    In addition to high-grade glioma, NUV-422 is currently being developed to treat HR+/HER2-advanced breast cancer (with or without brain metastasis) and metastatic castration-resistant prostate cancer (mCRPC)


    The Phase I/II study of NUV-422 for the treatment of adult relapsed or refractory high-grade gliomas and solid tumors is ongoing


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.